Texas 2025 - 89th Regular

Texas House Bill HB4014 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	89R11615 MCF-D
2	2	By: Bucy H.B. No. 4014
3	3
4	4
5	5
6	6
7	7	A BILL TO BE ENTITLED
8	8	AN ACT
9	9	relating to a study on the use of psychedelic therapies in the
10	10	treatment of certain conditions.
11	11	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
12	12	SECTION 1. (a) In this Act:
13	13	(1) "Department" means the Department of State Health
14	14	Services.
15	15	(2) "Psychedelic therapies" means the use of
16	16	3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or ketamine
17	17	to treat mental health or other medical conditions.
18	18	(b) The department, in consultation with Baylor College of
19	19	Medicine and the Center for Psychedelic Research and Therapy at
20	20	Dell Medical School at The University of Texas at Austin, shall
21	21	conduct a study on the use of psychedelic therapies for treatment of
22	22	post-traumatic stress disorder, depression, and other co-occurring
23	23	conditions.
24	24	(c) In conducting the study, the department shall:
25	25	(1) review clinical trials on the efficacy of using
26	26	psychedelic therapies in the treatment of post-traumatic stress
27	27	disorder, depression, and other co-occurring conditions;
28	28	(2) review current literature regarding the use of
29	29	psychedelic therapies in the treatment of post-traumatic stress
30	30	disorder, depression, and other co-occurring conditions;
31	31	(3) review actions of the United States Food and Drug
32	32	Administration regarding psychedelic therapies for treatment of
33	33	post-traumatic stress disorder, depression, and other co-occurring
34	34	conditions;
35	35	(4) evaluate treatment guidelines for use of
36	36	psychedelic therapies to treat post-traumatic stress disorder,
37	37	depression, and other co-occurring conditions and recommend
38	38	guidelines and best practices for providers; and
39	39	(5) evaluate patient access to current treatment for
40	40	post-traumatic stress disorder, depression, and other co-occurring
41	41	conditions and recommend legislative or other actions necessary to
42	42	ensure patient access to psychedelic therapies following approval
43	43	by the United States Food and Drug Administration, including
44	44	considerations of provider availability, affordability,
45	45	accessibility, training and licensure, and other regulatory
46	46	requirements.
47	47	(d) Not later than December 1, 2026, the department shall
48	48	submit to the governor, the lieutenant governor, the speaker of the
49	49	house of representatives, and the chair of the standing committee
50	50	of each house of the legislature with primary jurisdiction over the
51	51	department a written report that includes:
52	52	(1) the results of the study conducted under this
53	53	section; and
54	54	(2) any recommendations for legislative or other
55	55	action necessary to ensure patient access to psychedelic therapies
56	56	for treatment of post-traumatic stress disorder, depression, and
57	57	other co-occurring conditions after those therapies are approved by
58	58	the United States Food and Drug Administration.
59	59	(e) This Act expires September 1, 2027.
60	60	SECTION 2. This Act takes effect September 1, 2025.